<DOC>
	<DOCNO>NCT01248728</DOCNO>
	<brief_summary>This pilot , randomize , placebo-controlled trial omega-3 fatty acid autism . Autism , originally describe Kanner 1943 , among severe neurodevelopmental disorder . It Pervasive Developmental Disorder ( PDD ) affect social communicative function also characterize repetitive behaviors/restricted interest . It also frequently accompany significant aggression , self-injury , irritability hyperactivity , make care individual even great challenge family institutional setting . Autism severely impact affected individual family member , cause life-long functional impairment . In protocol investigator use term `` autism '' `` autism spectrum disorder ( ASD ) '' interchangeably refer Autistic disorder , Asperger Syndrome PDD-Not Otherwise Specified ( NOS ) .</brief_summary>
	<brief_title>Omega-3 Fatty Acids For Treatment Of Young Children With Autism ( OMG )</brief_title>
	<detailed_description>Currently risperidone medication approve Food Drug Administration ( FDA ) disorder , specifically irritability associate autism , although patient autism respond risperidone . No pharmacologic treatment approve use preschool child , although clear early intervention associate improved outcome . Behavioral educational therapy play significant role management autistic symptom . The history alternative treatment autism notable exaggerated benefit variety supplement , high dose vitamin ( e.g . B6 , magnesium ) , secretin . The current widespread use alternative/nutritional supplement patient autism without scientifically demonstrate efficacy , underscore necessity scientifically sound study conduct . Complementary alternative medical therapy ( CAM ) commonly employed family autistic child . Recent survey estimate prevalence use 30 % 95 % ( 1,2,3 ) . Omega-3 fatty acid report used 28.7 % patient ( 1 ) . However , two small case series small randomize study report population date . The investigator propose conduct randomize controlled trial omega-3 fatty acid preschooler ASD .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<criteria>1 . Male female outpatient 25 year age . 2 . Meet Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision ( DSMIV ) criterion . DSMIV criterion autism spectrum disorder , ( Autistic disorder , Asperger syndrome PDDNOS ) establish clinician expertise individual ASD base parent interview , Autism Diagnostic Observation Schedule ( ADO ) Autism Diagnostic Interview ( ADIR ) 3 . If already receive stable non pharmacologic educational , behavioral , dietary or/ natural health product intervention precede 3 month prior Screening , electively initiate new modify ongoing intervention duration study unless child 's condition worsen turn come treatment wait list . 4 . Have normal physical examination laboratory test result Screening . If abnormal , find ( ) must deem clinically insignificant Investigator . 5 . The parent must able speak understand English sufficiently allow completion study assessment . 1 . Patients born prior 35 week gestational age . 2 . Patients primary psychiatric diagnosis autism Screening . We aware primary psychiatric disorder unlikely diagnosed age group 3 . Patients medical history neurological disease , include , limited , epilepsy/seizure disorder ( except simple febrile seizure ) , movement disorder , tuberous sclerosis , fragile X , know genetic syndrome , know abnormal MRI/structural lesion brain . 4 . Patients medical condition might interfere conduct study , confound interpretation study result , endanger wellbeing . Patients evidence history malignancy significant hematological , endocrine , cardiovascular ( include rhythm disorder ) , respiratory , renal , hepatic , gastrointestinal disease , coagulation deficit . 5 . Patients take psychoactive medication ( ) ( e.g. , stimulant , antidepressant , antipsychotic , antiepileptic , anxiolytic , clonidine ) . 6 . Patients pharmacotherapy less 6 week . 7 . Patients participate another clinical trial 8 . Patients anticoagulants 9 . Patients know initiate change nonpharmacologic intervention course study . 10 . Patients unable tolerate venipuncture procedure blood sample . 11 . Patients take Omega3 supplement discontinue treatment six week prior enter study . 12 . Patients allergies ingredient omega3 ( study product ) placebo .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Autism Spectrum Disorder</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Omega-3 Fatty Acids</keyword>
	<keyword>Toddlers</keyword>
</DOC>